A recipient of nearly NT $ 700 million in government funding, and with 27.7 % of its stock held by the National Development Fund, TaiMed demonstrates just how determined the government is to push the development of the biotech and new pharmaceuticals industries in Taiwan.
在行政院國家發展基金入股 27.7 %、投資台幣近 7 億元的資金挹注之下，中裕可說是政府近年來大力扶植生技新藥產業發展的「指標」。